Plain-English translation of NCT06533358 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called MT1002 in patients who are experiencing a heart attack and need an emergency procedure called PCI (a catheter-based treatment to open blocked heart arteries). MT1002 is designed to work in two ways: it both prevents blood clots and stops platelets from clumping together, which are both important goals during this critical time.
Heart attacks happen when blood clots block arteries supplying the heart. While doctors can open these arteries with PCI, preventing new clots from forming is crucial. This medication aims to provide better clot prevention during and after the procedure.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the medication MT1002 as a single infusion during your hospital stay for the heart attack treatment. The medication is given intravenously (through an IV) with an initial dose followed by a 4-hour infusion. The study team will carefully monitor your safety throughout and may adjust the dose based on how you respond. Your participation involves being part of this dose-testing phase to help determine the safest and most effective dose for future patients.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Enrollment target
~20 participants
Started
February 2024
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Changsheng Ma, Medical phd
Beijing Anzhen Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.